Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Lymphatic Malformations

In brief

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.

Key facts

Study ID
NCT05948943
Run by
Novartis Pharmaceuticals
People needed
232
Starts
2023-11-24
Expected to finish
2033-05-02
Last updated by the study team
2026-07-14

Who can join

Age: any, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.